BioLineRx Ltd. (TLV:BLRX)

Market Cap	46.88M
Revenue (ttm)	105.41M
Net Income (ttm)	-33.59M
Shares Out	2.23B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	938,938
Average Volume	4,898,123
Open	2.100
Previous Close	2.100
Day's Range	2.100 - 2.200
52-Week Range	1.400 - 20.800
Beta	0.86
RSI	52.51
Earnings Date	May 25, 2025

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 28
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BLRX

Financial Performance

In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.

Financial numbers in USD